Dr Seymour serves as the President, Chief Executive Officer, and Managing Director of Seamless Therapeutics and is a member of the Board of Directors. During his distinguished career in human genetics and pharmaceutical research and development, he spearheaded Homology Medicines’ phenylketonuria (PKU) program, from concept to the world’s first gene therapy clinical trial for PKU in under 3 years. Dr Seymour has also held various senior leadership roles at Shire Pharmaceuticals and Pfizer and is a member of the Board of Directors of Ensoma and Iris Medicine. Dr Seymour received his BSc degree in Biology from the University of Delaware and MSc degree in Molecular Biology from Johns Hopkins University and his PhD and post-doctoral training in human genetics at the University of Pittsburgh.

Dr Kinch oversees R&D, Regulatory/Quality, CMC/Technical Operations, and Program Portfolio Management at Seamless Therapeutics. Before joining Seamless Therapeutics, she served as Chief Development Officer at Homology Medicines, where she supported Phase 1/2-readiness in PKU gene therapy/editing programs. Prior to Homology, Dr Kinch served as head of the Early Regulatory Sciences group at Biogen. Her experience building and leading high-performing teams and use of cross-functional strategies to advance research into clinical development has led to the clearance of INDs and CTAs for both gene transfer and gene-editing platforms. Dr Kinch holds an AB in Biochemistry from Mount Holyoke College and a PhD in Molecular Biophysics and Biochemistry from Yale University.